The estrogen receptor alpha-derived peptide ERα17p (P295-T311) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERα status

Molecular Oncology

Volumn 5, Issue 1, 2011, Pages 36-47

  Pelekanou, Vassiliki ^a,b   Kampa, Marilena ^a,b   Gallo, Dominique ^b   Notas, George ^a   Troullinaki, Maria ^a   Duvillier, Hugues ^b   Jacquot, Yves ^c   Stathopoulos, Efstathios N ^a   Castanas, Elias ^a   Leclercq, Guy ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b JULES BORDET INSTITUTE   (Belgium)

^c Centre National de la Recherche Scientifique   (France)

Author keywords

Apoptosis; Breast cancer cells (MCF 7, T47D, MDA MB 231, SK BR 3); Estrogen receptor

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA 17 P; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL FATE; CELL STRAIN MCF 7; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

EID: 78951477564     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2010.11.001     Document Type: Article

References (41)

1. Acconcia F., Ascenzi P., Bocedi A., Spisni E., Tomasi V., Trentalance A., Visca P., Marino M. Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol. Biol. Cell 2005, 16:231-237.
2. Amazit L., Pasini L., Szafran A.T., Berno V., Wu R.C., Mielke M., Jones E.D., Mancini M.G., Hinojos C.A., O'Malley B.W., Mancini M.A. Regulation of SRC-3 intercompartmental dynamics by estrogen receptor and phosphorylation. Mol. Cell. Biol. 2007, 27:6913-6932.
3. Barcellos-Hoff M.H., Akhurst R.J. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res. 2009, 11:202.
4. Barone I., Iacopetta D., Covington K.R., Cui Y., Tsimelzon A., Beyer A., Ando S., Fuqua S.A. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene 2010, 29:2404-2414.
5. Basu A., Mohanty S., Sun B. Differential sensitivity of breast cancer cells to tumor necrosis factor-alpha: involvement of protein kinase C. Biochem. Biophys. Res. Commun. 2001, 280:883-891.
6. Filardo E., Quinn J., Pang Y., Graeber C., Shaw S., Dong J., Thomas P. Activation of the novel estrogen receptor G protein-coupled receptor 30 (GPR30) at the plasma membrane. Endocrinology 2007, 148:3236-3245.
7. Gallo D., Jacquemotte F., Cleeren A., Laios I., Hadiy S., Rowlands M.G., Caille O., Nonclercq D., Laurent G., Jacquot Y., Leclercq G. Calmodulin-independent, agonistic properties of a peptide containing the calmodulin binding site of estrogen receptor alpha. Mol. Cell. Endocrinol. 2007, 268:37-49.
8. Gallo D., Jacquot Y., Cleeren A., Jacquemotte F., Laïos I., Laurent G., Leclercq G. Molecular basis of agonistic activity of ER 17p, a synthetic peptide corresponding to a sequence located at the N-Terminal part of the estrogen receptor ligand binding domain. Lett. Drug Design Discov. 2007, 4:346-355.
9. Gallo D., Haddad I., Duvillier H., Jacquemotte F., Laios I., Laurent G., Jacquot Y., Vinh J., Leclercq G. Trophic effect in MCF-7 cells of ERalpha17p, a peptide corresponding to a platform regulatory motif of the estrogen receptor alpha-underlying mechanisms. J. Steroid Biochem. Mol. Biol. 2008, 109:138-149.
10. Gallo D., Haddad I., Laurent G., Vinh J., Jacquemotte F., Jacquot Y., Leclercq G. Regulatory function of the P295-T311 motif of the estrogen receptor alpha - does proteasomal degradation of the receptor induce emergence of peptides implicated in estrogenic responses?. Nucl. Recept. Signal. 2008, 6:e007.
11. Gallo D., Jacquot Y., Laurent G., Leclercq G. Calmodulin, a regulatory partner of the estrogen receptor alpha in breast cancer cells. Mol. Cell. Endocrinol. 2008, 291:20-26.
12. Gallo D., Leclercq G., Jacquot Y. The N-terminal part of the ligand-binding domain of the human estrogen receptor?: a new target for estrogen disruptors. Medicinal Chemistry Research Progress 2009, 207-224. Nova, NY. G.P. Colombo, S. Ricci (Eds.).
13. Jacquot Y., Gallo D., Leclercq G. Estrogen receptor alpha-identification by a modeling approach of a potential polyproline II recognizing domain within the AF-2 region of the receptor that would play a role of prime importance in its mechanism of action. J. Steroid Biochem. Mol. Biol. 2007, 104:1-10.
14. Jacquot Y., Leclercq G. The ligand binding domain of the human estrogen receptor alpha: mapping and functions. Estrogens: Production, Functions and Applications 2009, 231-272. Nova, NY. J.R. Bartos (Ed.).
15. Jordan C. Historical perspective on hormonal therapy of advanced breast cancer. Clin. Ther. 2002, 24(Suppl. A):A3-A16.
16. Jordan V.C., Lewis-Wambi J.S., Patel R.R., Kim H., Ariazi E.A. New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast 2009, 18(Suppl. 3):S10-S17.
17. Kampa M., Nifli A.P., Charalampopoulos I., Alexaki V.I., Theodoropoulos P.A., Stathopoulos E.N., Gravanis A., Castanas E. Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. Exp. Cell Res. 2005, 307:41-51.
18. Kampa M., Pelekanou V., Castanas E. Membrane-initiated steroid action in breast and prostate cancer. Steroids 2008, 73:953-960.
19. Kessenbrock, K., Plaks, V., Werb, Z., 2010. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141, 52-67.
20. Leclercq G., Lacroix M., Laios I., Laurent G. Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells. Curr. Cancer Drug Targets 2006, 6:39-64.
21. Levin E. Rapid signaling by steroid receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295:R1425-R1430.
22. Levin E.R. Plasma membrane estrogen receptors. Trends Endocrinol. Metab. 2009, 20:477-482.
23. Li L., Li Z., Howley P.M., Sacks D.B. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J. Biol. Chem. 2006, 281:1978-1985.
24. Lonard D.M., O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 2006, 125:411-414.
25. Luo L.Y., Grass L., Diamandis E.P. Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. Clin. Chim. Acta 2003, 337:115-126.
26. Madak-Erdogan Z., Kieser K.J., Kim S.H., Komm B., Katzenellenbogen J.A., Katzenellenbogen B.S. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors. Mol. Endocrinol. 2008, 22:2116-2127.
27. Maximov P.Y., Lewis-Wambi J.S., Jordan V.C. The paradox of oestradiol-induced breast cancer cell growth and apoptosis. Curr. Signal Transduct. Ther. 2009, 4:88-102.
28. Metivier R., Reid G., Gannon F. Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep. 2006, 7:161-167.
29. Paliouras M., Diamandis E.P. Androgens act synergistically to enhance estrogen-induced upregulation of human tissue kallikreins 10, 11, and 14 in breast cancer cells via a membrane bound androgen receptor. Mol. Oncol. 2008, 1:413-424.
30. Pedram A., Razandi M., Kim J.K., O'Mahony F., Lee E.Y., Luderer U., Levin E.R. Developmental phenotype of a membrane only estrogen receptor alpha (MOER) mouse. J. Biol. Chem. 2009, 284:3488-3495.
31. Peng J., Sengupta S., Jordan V.C. Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer. Anticancer Agents Med. Chem. 2009, 9:481-499.
32. Sengupta S., Jordan V.C. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv. Exp. Med. Biol. 2008, 630:206-219.
33. Singha, P.K., Yeh, I.T., Venkatachalam, M.A., Saikumar, P., 2010. Transforming growth factor-beta (TGF-beta)-inducible gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast cancer. Cancer Res. 70, 6377-6383.
34. Taylor, S.E., Martin-Hirsch, P.L., Martin, F.L., 2010. Oestrogen receptor splice variants in the pathogenesis of disease. Cancer Lett. 288, 133-148.
35. Thomas P., Pang Y., Filardo E.J., Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 2005, 146:624-632.
36. Wang H., Yu D., Agrawal S., Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003, 54:194-205.
37. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem. Biophys. Res. Commun. 2005, 336:1023-1027.
38. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc. Natl. Acad. Sci. USA 2006, 103:9063-9068.
39. Weisz L., Damalas A., Liontos M., Karakaidos P., Fontemaggi G., Maor-Aloni R., Kalis M., Levrero M., Strano S., Gorgoulis V.G., Rotter V., Blandino G., Oren M. Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res. 2007, 67:2396-2401.
40. Wiercinska E., Naber H.P., Pardali E., van der Pluijm G., van Dam H., Ten Dijke P. The TGF-beta/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast. Cancer Res. Treat. 2010, e-pub ahead of print, DOI: 10.1007/s10549-10010-11147-x.
41. Wurtz S.O., Schrohl A.S., Mouridsen H., Brunner N. TIMP-1 as a tumor marker in breast cancer-an update. Acta Oncol 2008, 47:580-590.